Michael Fonstein

Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. It focuses on oncology and acute radiation syndrome. It offers Entolimod, Mobilan, CBL0137, and SA-702. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Buffalo, NY.

Founded in 1997, Chicago-based Integrated Genomics™ specializes in research in microbial genomics, biochemistry, and gene expression. Its scientists has broad experience in both in silico and wet lab sequencing, research and development with more than 100 relevant publications in these areas. Integrated Genomics™ has particularly long-standing relationships and active research in the area of lactic acid bacteria and pathogenic microbes, as well as a broad customer base across industry, academic and government institutions. Integrated Genomics™' products and services are based on ERGO™, its web-based genome analysis platform. ERGO™ integrates proprietary functional genomic data, metabolic reconstructions, expression profiling, and biochemical and microbiological data with publicly available information. Focused on microbial genomics, ERGO™ provides better and faster identification of gene function across all organisms. In 2010 Integrated Genomics, Inc.'s business operations were transitioned to a new corporation, IG Assets, Inc. With the original Integrated Genomics' team, IG Assets continues to provide the same ERGO-based microbial genomic products and service.

Incuron LLC develops anticancer drugs. It provides an innovative pipeline of drugs to treat oncology and autoimmune disease for the global markets. The firm is a joint venture between Bioprocess Capital Ventures and Cleveland BioLabs. The company was founded in January 2010 and is headquartered in Moscow, Russia.

Panacela Labs, Inc. specializes in oncology and orphan drug development. It operates as a clinical stage biotech firm that develops anticancer drug products. The firm provides its Mobilan drug for prostate cancer therapy. The company was founded in 2011 and is headquartered in Buffalo, NY.

Accelerated Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in development of pre-existing pharmaceutical products for the treatment of various cancer indications. It offers a platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications under the Picoplatin brand. The company was founded by Michael Fonstein, Ekaterina E. Nikolaevskaya and Dmitry Prudnikov in May 2014 and is headquartered in Westport, CT.